Healthcare Industry News: TrueBeam
News Release - October 5, 2010
Varian Medical Systems and Imris to Co-Develop Revolutionary New MR-Guided Radiation Therapy SystemPALO ALTO, CA and WINNIPEG, MB, Oct 5 (Healthcare Sales & Marketing Network) - Varian Medical Systems Inc., (NYSE: VAR ; "Varian") and IMRIS Inc. (TSX: IM ; "IMRIS") have concluded an agreement to co-develop an innovative new MR-guided radiation therapy system for use in treating a variety of cancers.
MR is the gold standard for soft tissue imaging. By leveraging IMRIS's proprietary technology and integrating the exquisite detail of MR imaging with the extensive treatment delivery capabilities of the TrueBeam system, the two companies expect to enhance the effectiveness of radiation therapy.
"We are seeking to augment physicians' ability to target cancerous tissue very precisely, even in areas of the body that are difficult to image," said Dow Wilson, president of Varian's Oncology Systems business. "Many studies have shown that increased treatment accuracy can reduce the impact on healthy tissues around a targeted tumor."
The solution is being designed to permit a high-field MRI scanner to move in and out of the radiation therapy room on demand, providing MR imaging to very precisely confirm a tumor's location prior to treatment, and again during the session as needed, all without having to move the patient from the treatment couch or transport the patient to and from another room, as would be required today. Consistent with IMRIS's systems for neurosurgery, neurovascular and cardiac applications, the radiation therapy systems are expected to be offered as multi-room configurations and include independent MR-simulation capabilities for the MR system to further enhance financial utility for hospitals.
IMRIS first began development of its MR-guided radiation therapy program in 2008 in collaboration with the University Health Network (UHN) in Toronto, Canada. A state of the art IMRIS 3T MR-simulation suite was installed in 2009 at UHN's Princess Margaret Hospital in Toronto, a world-renowned cancer research and treatment centre. Princess Margaret Hospital ("PMH") will complement the development work by Varian and IMRIS by providing the clinical expertise and environment for building and testing the first of these systems.
Dr. David Jaffray, Head of Radiation Physics at PMH said, "There are certain clinical situations that challenge even the most advanced methods available for targeting cancer. Tightly integrating MR imaging into radiation treatment will allow us to adapt the therapy to the individual patient and will open exciting new avenues of research to further improve the effectiveness of radiation therapy."
Following successful completion of the development stage of this project, and subject to necessary regulatory approvals, the companies anticipate co-branding the new MR-guided radiation therapy suite and leveraging Varian's global presence and leadership position in the fields of radiotherapy and radiosurgery to market the new product.
"More than 10 million new cancer cases occur throughout the world each year, and in the U.S., about half of all cancer patients receive some type of radiation therapy during the course of their treatment," said David Graves, Chairman and CEO, IMRIS. "By combining IMRIS's image guided capabilities with the scale and scope of Varian's operations we have a significant opportunity to accelerate time to market and extend the benefits of MR imaging to radiation treatment rooms around the world."
Analyst Conference Call Today
IMRIS will host a conference call to discuss the announced agreement between Varian and IMRIS today at 4:30 pm ET. Following management's presentation, there will be a question-and-answer session for analysts and institutional investors. To participate in the teleconference, please call 1-877-974-0448 or 1-416-644-3421 (conference code 4372285). To access the live audio webcast, please visit IMRIS's website at www.imris.com. A taped rebroadcast will be available to listeners following the call until midnight (ET) on October 12, 2010. To access the rebroadcast, please call 416-640-1917 or 877-289-8525 and enter passcode 4372285(number sign).The webcast will also be archived on IMRIS's website.
About Varian Medical Systems
Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection. Varian Medical Systems employs approximately 5,000 people who are located at manufacturing sites in North America, Europe and China and approximately 79 sales and support offices around the world. For more information, visit www.varian.com.
IMRIS (TSX: IM ) is a global leader in providing image guided therapy solutions. These solutions feature fully integrated surgical and interventional suites that incorporate magnetic resonance, fluoroscopy and computed tomography to deliver on demand imaging during procedures. The Company's systems serve the neurosurgical, cardiovascular and neurovascular markets and have been selected by leading medical institutions around the world. For further information visit www.imris.com.
This press release may contain or refer to forward-looking information based on current expectations. In some cases, forward-looking statements can be identified by terminology such as "anticipate", "may", "expect", "believe", "prospective", "continue" or the negative of these terms or other similar expressions concerning matters that are not historical facts. These statements should not be understood as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that actual results will be consistent with such statements. Forward-looking statements are subject to significant risks and uncertainties, and other factors that could cause actual results to differ materially from expected results. These forward-looking statements are made as of the date hereof and we assume no responsibility to update or revise them to reflect new events or circumstances.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.